{"id":"W4407095946","doi":"10.1016/s1470-2045(24)00674-0","title":"Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Clovis Oncology","keywords":"Oncology; Ovarian cancer; Medicine; Open label; Internal medicine; Chemotherapy; BRCA mutation; Cancer; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001808168,0.001602187,0.002972362,0.0003868787,0.000305774,0.001115089,0.001053511,0.001789312,0.007169597],"category_scores_gemma":[0.002195005,0.0005563372,0.002830894,0.0004443395,0.001066929,0.001211792,0.0004181614,0.004620349,0.001189811],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008464935,"about_ca_system_score_gemma":0.0007846708,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001301816,"about_ca_topic_score_gemma":0.003334578,"domain_scores_codex":[0.9992383,0.0004647232,0.00003027533,0.0001051315,0.00004466359,0.0001169413],"domain_scores_gemma":[0.9990537,0.0004101081,0.0001790957,0.00007531836,0.00004468631,0.0002371398],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9626512,0.002419531,0.0003907722,0.0009068301,0.00181735,0.00004256399,0.00005027839,0.0006165171,0.001653109,0.0001651801,0.00132462,0.02796207],"study_design_scores_gemma":[0.9542359,0.04155431,0.001306933,0.00006752665,0.0007420848,0.00004599383,0.00002624716,0.0004225174,0.0002571706,0.0002795946,0.001042521,0.00001911462],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9584879,0.02608346,0.001368561,0.002316852,0.001498888,0.002371666,0.002288518,0.0003469061,0.005237279],"genre_scores_gemma":[0.9751561,0.008849065,0.002065954,0.002376436,0.0005815657,0.002143989,0.002045842,0.00006696469,0.006714032],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007169597,"threshold_uncertainty_score":0.02398473,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1765830987533513,"score_gpt":0.484240699301871,"score_spread":0.3076576005485196,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}